Gilead falls on lower quarterly product sales
ReutersOct 31, 2025 9:26 AM
Shares of drugmaker Gilead GILD.O fall 1.6% to $116.53 premarket
Co's Q3 product sales decrease 2% to $7.3 billion
GILD says it saw lower sales for its cell therapies Yescarta and Tecartus in the quarter
Co reports Q3 profit of $2.43/shr vs analysts' average estimate of $2.13/shr - LSEG data
Total Q3 revenue up 3% to $7.77 billion vs analysts' average estimate of $7.45 billion
Up to last close, stock up 28.2% YTD
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
Tesla’s 2025 Shareholder Meeting Showdown: Musk’s Leadership and Tesla’s Crossroads
TradingKey - Tesla (TSLA), the electric vehicle leader, will hold its 2025 Annual Shareholder Meeting on November 6. Dubbed by CEO Elon Musk as a moment that will “decide Tesla’s future and shape the world’s,” the event centers on one pivotal question: Will shareholders approve Musk’s proposed $1 TTradingKey
8 hours ago
What Drove the 'Black Tuesday' Sell-Off? Three Key Factors Behind the U.S. Stock Plunge
TradingKey - On November 4, 2025, U.S. markets suffered a sudden and sharp selloff — dubbed “Black Tuesday” — with the Nasdaq posting its largest single-day drop in a month. The rout unfolded amid growing economic and political instability, as a record-long government shutdown worsened systemicTradingKey
11 hours ago
IonQ Stock Price Skyrockets 300% in a Year, But Recently Drops 30%—Is IonQ Still a Buy?
Is IonQ worth buying? With a recent decline of nearly 30% over the past month, is now the time to buy? How much further could IonQ's stock rise?TradingKey
12 hours ago
Novo Nordisk Q3 Earnings Preview: New CEO, Board Overhaul — Can the U.S. Weight-Loss Market Turn Around?
TradingKey - Novo Nordisk (NVO), one of Europe’s pharmaceutical giants and a leader in the weight-loss drug race, will report its Q3 2025 earnings before market open on November 5. Wall Street expects a modest rebound from Q2’s worst growth in four years, but significant pressure on profits remains.TradingKey
Tue, Nov 4
Palantir Q3 2025 Earnings: Blowout Performance Can’t Hide an AI Bubble， Four Growing Risks Behind a Nearly 1,000x Valuation
TradingKey – After the close of trading on November 4, “AI application King” Palantir Technologies (PLTR) reported its third-quarter earnings for fiscal year 2025. Despite a blowout quarter, surging top-line growth, and a flood of commercial orders, the stock plunged in after-hours trading.TradingKey
Tue, Nov 4
